Integrated probe for realizing immediate fluorescence development and targeted photo-thermal / photodynamic therapy in prostatic cancer operation
By coupling RNAaptamer targeting PSMA with ICG, targeted fluorescence development and photothermal/photodynamic therapy for prostate cancer tissues are achieved, which solves the problem of lack of specificity of traditional fluorescent developer on prostate cancer tissues and improves surgery The accuracy and safety of the treatment enhancement.
Patent Information
- Application Number
- CN202411234461.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-12-03
Smart Images

Figure CN119055800A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection and biomedicine technology, and specifically relates to an integrated probe for realizing immediate fluorescence development and targeted photothermal / photodynamic therapy during prostate cancer surgery. Background Art
[0002] Radical prostatectomy is the best treatment option for early and localized PCa. In recent years, intraoperative fluorescence imaging technology has gradually become an important tool for cancer lesion tracking in tumor surgery. However, traditional fluorescent contrast agents lack specificity for PCa tissue, which makes it difficult to accurately distinguish cancerous tissue from normal tissue during surgery, increasing the risk of tumor omission and postoperative recurrence. In addition, this limitation leads to prolonged operation time and increased trauma, which seriously affects the patient's prognosis. Therefore, there is an urgent need for faster and more accurate imaging technology to improve surgical resection efficiency, reduce intraoperative margin positivity, reduce postoperative recurrence, prolong patient survival time and improve quality of life.
[0003] Prostate-Specific Membrane Antigen (PSMA) is a membrane-bound enzyme that is mainly expressed on the surface of prostate cells and is overexpressed on PCa cells, which makes PSMA an ideal target for the diagnosis and treatment of PCa. At present, the treatment strategies for PSMA mainly include radionuclide labeling of PSMA small molecule antibodies, immunotherapy targeting PSMA, and construction of drug delivery systems. For example, Chinese invention patent CN115572320A discloses a PCaPET / NIR dual-mode imaging molecular probe 68Ga-XY-PSMA-ICG, which can safely, efficiently and accurately detect the expression of PCaPSMA in vivo, has good biocompatibility and a long in vivo circulation time, is suitable for the diagnosis of clinical PCa and intraoperative navigation, and has potential clinical application value.
[0004] Aptamer is a single-stranded DNA or RNA screened from a random nucleic acid library by in vitro screening technology (Systematic Evolution of Ligands by Exponential Enrichment, SELEX), which can efficiently and stably recognize and bind to specific target molecules. Compared with traditional antibodies, aptamers have a small molecular weight and are easier to penetrate biological barriers; they are easy to synthesize in vitro, avoiding the complexity and ethical issues caused by animal immunity; after modification, aptamers have stable properties and functions and are not easy to denature or degrade. Therefore, aptamers can not only be used for the delivery of molecular carriers (such as drugs, siRNA and fluorescent markers), but also show strong application potential in many fields such as targeted diagnosis and treatment of diseases, molecular imaging, and biosensors.
[0005] Indocyanine green (ICG) is currently the only near-infrared (NIR) fluorescent imaging agent approved by the U.S. Food and Drug Administration (FDA) and is widely used in various medical diagnoses. However, for most tumors except liver cancer, ICG lacks specific targeting. Its application in most tumor surgeries is mainly based on spatial anatomical tracing of vascular circulation rather than specific pathological imaging of tumors, which significantly restricts its application value in tumor diagnosis and treatment. In addition, ICG will produce a photothermal effect under 808nm NIR light irradiation, which significantly increases the local temperature and can also produce highly oxidative reactive oxygen species (ROS) to induce target cell death. Therefore, ICG is also used in traditional photothermal therapy (PTT), mild photothermal therapy (mPTT) and photodynamic therapy (PDT). Therefore, giving ICG targeting will bring breakthrough advantages to tumor diagnosis and treatment.
[0006] In summary, if ICG can be coupled with RNAaptamer targeting PSMA, it will be possible to achieve targeted imaging of tumors during surgery as well as targeted photothermal and photodynamic therapy of tumors, thereby realizing "integrated diagnosis and treatment." Summary of the invention
[0007] In view of the shortcomings of the existing technology, the present invention couples the PSMA-targeted RNA aptamer with ICG, and can achieve targeted pathological-grade fluorescence imaging and photothermal / photodynamic therapy of PCa tissues under the guidance of the PSMA RNA aptamer, thereby realizing "integrated diagnosis and treatment".
[0008] To achieve the above object, the present invention provides the following technical solutions:
[0009] The present invention provides an integrated diagnosis and treatment probe for PCa, wherein the probe comprises RNAaptamer A10-3.2 targeting PSMA and ICG, wherein the nucleotide sequence of A10-3.2 is
[0010] 5'-GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCU-3'.
[0011] The A10-3.2-ICG probe of the present invention provides the possibility for achieving immediate intraoperative targeted fluorescence imaging and photothermal / photodynamic therapy of PCa.
[0012] Preferably, the recommended dosage of the probe during fluorescence imaging and photothermal / photodynamic therapy is not less than 6 nmol / mouse.
[0013] The stable targeting function of A10-3.2-ICG fully depends on the effective folding of its spatial structure. Preferably, the effective folding temperature of the probe is: heating at 95°C for 5 min, then heating to 26.6°C at a rate of 4.6°C / min, and maintaining in the dark.
[0014] Preferably, A10-3.2 and ICG are covalently bound at a mass ratio of 1:1.
[0015] Preferably, the PCa is PSMA-overexpressing (positive) PCa.
[0016] The present invention also provides the use of the probe in achieving immediate fluorescence imaging of PCa tumors during surgery.
[0017] The present invention also provides the use of the probe in achieving PCa targeted photothermal / photodynamic therapy.
[0018] The present invention also provides a method for preparing the probe, specifically: covalently combining A10-3.2 and ICG by coupling carboxyl activated ester with amino group.
[0019] The preparation method comprises the following steps:
[0020] S1, performing amino modification on the 5' end of A10-3.2 to obtain 5'AmC6-A10-3.2;
[0021] S2, combining ICG with NHS to generate ICG-NHS;
[0022] S3. Use Milli-Q water to prepare A10-3.2C5-NH2 into a 1-2 mM stock solution, and use DMSO to dissolve ICG-NHS into an 8-12 mM solution. Then add the two solutions to the MES solution and incubate at room temperature for 8-15 h.
[0023] More preferably, the concentration of the MES solution is 90-110 mM, and the pH is 5-6.
[0024] More preferably, the concentration of 5'AmC6-A10-3.2 in the MES solution is 10-12 μM.
[0025] More preferably, the molar amount of ICG-NHS is twice that of A10-3.2C5-NH2.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] (1) Compared with ICG, the A10-3.2-ICG coupled probe has a rapid and sensitive targeting response to PCa in vivo, and can achieve immediate fluorescence visualization of PCa tissue at the nanomolar level, with active targeting enrichment characteristics; compared with ICG, A10-3.2-ICG has a significantly better effect on PCa visualization under fluorescence laparoscope, which is a visualization with pathological significance and greatly improves the timeliness and accuracy of intraoperative PCa visualization.
[0028] (2) Compared with ICG, A10-3.2-ICG can specifically bind to the surface of PSMA-positive PCa cells and internalize into cancer cells, thereby achieving faster and more accurate imaging with a lower developer dose and maintaining a sufficient retention time in cancer tissues. This overcomes the shortcomings of ICG, such as its lack of specific targeting to PCa and its rapid metabolism.
[0029] (3) Compared with ICG, A10-3.2-ICG has a better targeted photothermal / photodynamic therapy effect on PCa cells under 808nm NIR band light due to its active targeting and cell internalization effects. It can also achieve PCa photothermal / photodynamic therapy inside cells to a certain extent, thus supplementing the non-invasive treatment of PCa. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The mass spectrum information of 5'AmC6-A10-3.2 and A10-3.2-ICG.
[0031] Figure 2Comparison of in vivo imaging of A10-3.2-ICG and ICG. Note: (a) Fluorescence imaging of A10-3.2-ICG and ICG in 22Rv1 tumor-bearing nude mice before (before) and at different time points after injection (0min, 1h, 2h, 3h). The upper row shows the imaging effect of A10-3.2-ICG, and the lower row shows the imaging effect of ICG; (b) 3h after injection, the fluorescence distribution of major organs and tumors. The color bar in the figure shows the radiant efficiency of the fluorescence intensity, from low (red) to high (yellow), in photons / second / square centimeter / microwatt (p / s / cm 2 / μW).
[0032] Figure 3 The figure is an independent comparison of fluorescence laparoscopic tumor imaging of A10-3.2-ICG and ICG. Note: After 6nmol A10-3.2-ICG and 6nmol ICG were injected into 22Rv1 tumor-bearing nude mice, the tumor imaging effect under fluorescence laparoscopy at 0min, 1h, 2h and 3h; (a) A10-3.2-ICG: The first row: Overlay, green fluorescence indicates signal intensity, the brighter the green, the stronger the signal; The second row: Monochromatic, the white area indicates the fluorescence signal, the brighter the white, the stronger the signal; The third row: Intensity Map, the color from blue (weak) to red (strong) indicates the fluorescence intensity; (b) ICG: The first row: Overlay, green fluorescence indicates signal intensity, the brighter the green, the stronger the signal; The second row: Monochromatic, the white area indicates the fluorescence signal, the brighter the white, the stronger the signal; The third row: Intensity Map, the color from blue (weak) to orange (strong) indicates the fluorescence intensity.
[0033] Figure 4 This is a combined comparison of fluorescence laparoscopic tumor imaging of A10-3.2-ICG and ICG. Note: Comparison of tumor imaging effects of 22Rv1 tumor-bearing nude mice injected with 6nmol A10-3.2-ICG and 6nmol ICG; Upper row: Overlay, showing fluorescence superposition images at different time points, green fluorescence signal represents the local presence of fluorescence signal in vivo; Middle row: Monochromatic, showing monochrome fluorescence images at different time points, white area indicates the presence of fluorescence signal, gray background is non-fluorescent signal area; Lower row: Intensity Map, showing the fluorescence intensity distribution map at different time points, the darker the color (from green to orange), the stronger the signal.
[0034] Figure 5Local visualization of subcutaneous tumors exposed to A10-3.2-ICG. Note: (a) Local fluorescence imaging: Upper figure: Overlay, showing the fluorescence signal of subcutaneous tumor in 22Rv1 tumor-bearing nude mice 3 hours after injection of 6nmolA10-3.2-ICG, the green area is the fluorescently labeled tumor tissue; Middle figure: Monochromatic, showing the intensity distribution of fluorescence signal, the white area indicates the presence of fluorescence signal, and the gray background is the non-fluorescent signal area; Lower figure: Intensity Map, showing the relative intensity of fluorescence signal, the darker the color (from green to orange), the stronger the signal; (b) Fluorescence imaging of major organs and tumors 3 hours after injection of 6nmolA10-3.2-ICG in 22Rv1 tumor-bearing nude mice: Upper figure: Overlay, the green area is the fluorescence signal; Middle figure: Monochromatic, showing the fluorescence signal intensity comparison, the white area indicates the presence of fluorescence signal, and the gray background is the non-fluorescent signal area; Lower figure: Intensity Map, showing the relative intensity of fluorescence signal, the darker the color (from green to orange), the stronger the signal.
[0035] Figure 6 Fluorescence laparoscopic tumor imaging of A10-3.2-ICG. Note: (a) In vivo fluorescence imaging (scale bar 40 μm): After injection of 12 nmol A10-3.2-ICG, fluorescence imaging of the tumor of 22Rv1 tumor-bearing nude mice was performed at 0 min, 1 h and 1.5 h, respectively; the figure shows three imaging modes (Overlay, Monochromatic and Intensity Map), showing the distribution and intensity of the fluorescence signal in the tumor site; (b) Fluorescence imaging of major organs: Fluorescence imaging of the major organs and tumors of nude mice was performed 2 h after A10-3.2-ICG injection; by showing the fluorescence distribution, the fluorescence signals of the tumor and kidney were shown at close range.
[0036] Figure 7 Comparison of ROS generation in three PCa cell lines after mPTT. Note: (a) Fluorescence microscopy images (scale bar 40μm) show the ROS generation of 22Rv1, C4-2 and PC3 cells under different treatment conditions. Treatment conditions include PBS (control group), laser irradiation only (Laser), A10-3.2 combined with laser irradiation (A10-3.2+L), ICG combined with laser irradiation (ICG+L) and A10-3.2-ICG combined with laser irradiation (A10-3.2-ICG+L). The changes in fluorescence signal intensity vary among different treatment groups; (b) The quantitative analysis results of fluorescence intensity (au) show that there are differences in ROS generation levels among different treatment groups. The bar graph shows the fluorescence intensity of each cell line under different treatment conditions. Significant differences compared with the PBS group:** p<0.01, *** p<0.001, **** p<0.0001; significant difference compared with ICG+L group: ## p<0.01, ### p<0.001.
[0037] Figure 8 Figure 2 shows the cell survival / death assay of three PCa cell lines after mPTT. (a) Fluorescence microscopy images show the ratio of live cells (green) to dead cells (red) in three PCa cell lines, 22Rv1, C4-2, and PC3, under different treatment conditions. Figure 7 Experiment; (b) The quantitative analysis results of the ratio of cell survival to cell death are shown in the form of bar graphs, reflecting the percentage of live cells (blue) and dead cells (red) in 22Rv1, C4-2 and PC3 cell lines under different treatment conditions. Significant differences compared with the PBS group: ** p<0.01, *** p<0.001, **** p<0.0001; significant difference compared with ICG+L group: ## p<0.01, ### p<0.001.
[0038] Fig. 9 This is the gentle photothermal treatment process of A10-3.2-ICG targeting 22Rv1 tumor-bearing nude mice. Note: 22Rv1 tumor cells formed subcutaneous tumors in 4-week-old nude mice. A10-3.2-ICG was injected into the tail vein on days 7 and 14 of tumor formation, and 808nm laser irradiation was performed for 5 minutes. The treatment temperature was monitored in real time. The nude mice were euthanized and samples were collected 21 days after tumor formation.
[0039] Fig.10 Real-time infrared temperature monitoring of mild photothermal therapy for nude mice bearing 22Rv1 tumors targeted by A10-3.2-ICG. Note: Real-time infrared thermal imaging: Real-time temperature changes of the center, highest and lowest temperature points of the nude mouse tumor from 0 to 5 minutes of mild photothermal therapy, unit: °C.
[0040] Fig.11This is the inhibitory effect of mPTT on 22Rv1 tumor-bearing nude mice. Note: Figure (a) is the overall picture of the nude mice in the control group (Control) and the mPTT group at the end of the experiment. In the picture, ten nude mice are divided into two groups, the upper row is the Control group, and the lower row is the mPTT group. The background scale is in cm; Figure (b) is the tumor after removal. The upper row is the mPTT group, and the lower row is the Control group tumor. The tumors are arranged in size from left to right; Figure (c) is the trend of nude mouse body weight changes during the experiment. The purple curve represents the Control group and the red curve represents the mPTT group; Figure (d) is the curve of tumor volume changes over time. The purple curve represents the Control group and the red curve represents the mPTT; Figure (e) The final weight of the tumor: the purple column on the left represents the Control group, and the red column on the right represents the mPTT group. The data are expressed as mean ± standard deviation (n = 5; * p<0.05, **** p<0.0001) DETAILED DESCRIPTION
[0041] The specific embodiments of the present invention are further described below. It should be noted that the description of the following embodiments is only used to help understand the present invention and does not constitute a limitation of the present invention. In addition, the technical features in each embodiment described below can be combined with each other as long as they do not conflict with each other.
[0042] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used are obtained through conventional commercial channels unless otherwise specified.
[0043] In the following examples, the synthesis of A10-3.2-ICG was fully entrusted to Xi'an Kaixin Biotechnology Co., Ltd. Example: Synthesis of an integrated probe for immediate fluorescence imaging of PCa tumors and targeted photothermal / photodynamic therapy
[0044] 1. Aptamer Primer Synthesis
[0045] The solid phase phosphoramidite triester method is used to connect the nucleotide monomers one by one to the 3' solid phase carrier through a four-step cycle reaction: deprotection, coupling, capping, and oxidation, and modification tags are added at the corresponding positions during the process.
[0046] The synthesized oligonucleotide was chemically cleaved from the solid support (CPG) and the protecting group was removed by aminolysis. After the crude product passed the inspection, it was purified by HPLC to separate different impurities to obtain the pure target product: 5'AmC6-A10-3.2 (5'-Amino-C6-GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCU). Finally, the pure target product was detected by LTQ-MS mass spectrometer ( Figure 1), and use an ELISA instrument to quantitatively package the qualified pure product at A260 (10nmol / tube), and then use a vacuum dryer to dry the sample to a dry powder.
[0047] The equipment and reagents involved in this step are shown in the following table:
[0048] Reaction steps equipment Reagents synthesis oligo synthesizer Nucleic acid monomer, acetonitrile, activator, oxidant Aminolysis Ammonia solution Ammonia purification High performance liquid chromatography Chromatographic mobile phase Quality Inspection LC-MS Mass Spectrometer Mass spectrometry mobile phase Packaging ELISA instrument, centrifugal concentration and drying instrument Ultrapure water, TE buffer
[0049] 2. Chemical coupling of ICG and aptamer:
[0050] Carbodiimide coupling reaction is a chemical reaction commonly used to connect carboxyl groups and amino groups into amide bonds. It is widely used in peptide synthesis and protein modification in the fields of biochemistry and organic chemistry. Among them, the NHS ester method is a common technique in carbodiimide coupling reactions.
[0051] The present invention uses a method of coupling carboxyl activated ester with amino group to covalently bind the oligonucleotide chain to ICG:
[0052] (1) 5'AmC6-A10-3.2 was purified by HPLC and prepared into a stock solution of about 1 mM using Milli-Q water and stored at -20°C until use. ICG-NHS (Kaixin Biotechnology, China) was dissolved in DMSO to prepare a 10 mM solution.
[0053] (2) To maintain the pH stability of the reaction, A10-3.2C5-NH2 was added to the MES solution (100 mM, pH 5.5) until its concentration reached 11 μM. Then, excess ICG-NHS (its molar amount was twice that of the oligonucleotide molecule) was added to the oligonucleotide molecule and incubated at room temperature overnight. 2. Ultrafiltration device was used to remove excess ICG and salt in the solution (the solution was loaded into the filter column, filled with Milli-Q water to the 2 ml mark, and centrifuged at 25 ° C and 2500g for about 20 min. This step was repeated 3 times). Finally, mass spectrometry was used for characterization ( Figure 1 ) to prepare the integrated diagnosis and treatment probe A10-3.2-ICG.
[0054] The molecular formula and process of the reaction are as follows:
[0055]
[0056] Experimental Example 1: Immediate tumor targeting fluorescence imaging experiment using probe A10-3.2-ICG
[0057] Nine 4-week-old athymic male BALB / c nude mice were purchased, and 100 μl of a mixture of PBS and Matrigel was prepared at a volume ratio of 1:1. 5 × 106 22Rv1 cells were implanted subcutaneously on the right chest wall of nude mice. After 2 weeks, the tumor was successfully formed with an average diameter of about 10 mm. Nude mice were anesthetized by intraperitoneal injection of pentobarbital (60 mg / kg), and 6 nmol effectively folded A10-3.2-ICG, 6 nmol ICG, and 12 nmol effectively folded A10-3.2-ICG were injected into the tail vein. Small animal live imaging and fluorescence laparoscope were used to dynamically monitor the changes and distribution of fluorescence signals in real time.
[0058] Small animal in vivo imaging Figure 2 As shown, Figure (a) shows the fluorescence imaging results of nude mice at different time points (before injection, 0min, 1h, 2h, 3h) after injection of A10-3.2-ICG (upper row) and ICG (lower row). A10-3.2-ICG quickly accumulated in the subcutaneous tumor site of nude mice after injection, and continued to show strong fluorescence signals within 3h. After injection, the fluorescence signal of ICG was mainly concentrated in the liver, and gradually weakened over time, indicating that it has no tumor targeting and is rapidly metabolized by the liver. Figure (b) shows the fluorescence imaging results of the main organs (heart He, liver Li, spleen Sp, lung Lu, kidney Ki) and tumors (Tu) of nude mice after injection of A10-3.2-ICG. A10-3.2-ICG mainly shows strong fluorescence signals in tumors and kidneys, while the fluorescence signals in other organs are weak. This further shows that A10-3.2-ICG has good tumor targeting and can effectively accumulate at the tumor site, thereby enhancing the imaging effect. Compared with ICG, A10-3.2-ICG has better tumor targeting and imaging effects, which is of great significance for the early detection and diagnosis of tumors.
[0059] Fluorescence laparoscopy results Figure 3As shown in the figure, Figure (a) and Figure (b) respectively show the effect of A10-3.2-ICG and ICG on fluorescence imaging of tumors at different time points (0min, 1h, 2h and 3h). A10-3.2-ICG: Overlay: Green fluorescence shows the location of the tumor. At 0min, the fluorescence signal is concentrated in the tumor site. As time goes by, the fluorescence signal gradually diffuses, but the tumor site can still be clearly marked; Monochromatic: The brightness changes of the tumor site can be observed. The brightness is highest at 0min, and the brightness gradually decreases as time goes by; Intensity Map: It shows the intensity distribution of the fluorescence signal. At 0min, the intensity is concentrated and strong. As time goes by, the signal intensity gradually decreases, but the tumor site can still be clearly distinguished. ICG: In the three modes, at 0min, due to the transient cycle development, the overall fluorescence signal of the nude mouse is more obvious. As time goes by, the fluorescence signal rapidly diffuses and weakens, the marking of the tumor site is unclear, and there is almost no signal at the tumor site. It can be seen that the fluorescence signal of A10-3.2-ICG remains relatively stable at the tumor site from 0min to 3h, and the tumor site can be continuously marked. ICG is mainly circulated into the liver for rapid metabolism and has no specific signal at the tumor site. Therefore, A10-3.2-ICG exhibits excellent targeting, stability and sustainability in tumor imaging.
[0060] Fluorescence laparoscopy results Figure 4 As shown in the figure, the distribution of A10-3.2-ICG and ICG in experimental mice at different time points (0min, 1h, 2h, 3h) under three imaging modes. ICG diffuses rapidly after injection, the signal intensity is weak and dispersed, and the fluorescence signal gradually weakens throughout the experiment. The fluorescence signal of A10-3.2-ICG appears to be more concentrated and persistent at the tumor site, showing its better tumor targeting and fluorescence signal retention effects. A10-3.2-ICG not only develops immediately, but also can still show obvious fluorescence signals at the tumor site for a long time (such as 3h). The experimental results clearly show the performance difference between A10-3.2-ICG and ICG in tumor development, indicating that A10-3.2-ICG has great application potential in tumor diagnosis and immediate intraoperative development.
[0061] Fluorescence laparoscopy results Figure 5As shown in the figure, after 3 hours of liver and kidney metabolism, the subcutaneous tumor was exposed and locally developed. (a) The subcutaneous tumor development effect under three modes is shown, indicating that A10-3.2-ICG successfully labeled the tumor tissue, making it clearly visible in the image and highlighting the morphology and location of the tumor. (b) The figure shows the fluorescence development effect of major organs and tumors. The tumor tissue showed significant fluorescence signals after A10-3.2-ICG labeling, proving the accumulation of A10-3.2-ICG in the tumor, which is of great significance for the intraoperative development of PCa cancer foci.
[0062] Fluorescence laparoscopy results Figure 6 As shown, (a) shows the tumor imaging effect in three modes at different time points after 12nmol A10-3.2-ICG was injected into nude mice. 0min: the tumor site showed obvious fluorescence, and the markers began to concentrate in the tumor area; 1h: the green fluorescence intensity increased significantly, the fluorescence was more concentrated in the tumor site, and a stronger fluorescence signal was shown; 1.5h: the fluorescence intensity continued to increase, the fluorescence in the tumor site was more obvious, the fluorescent markers were highly concentrated in the tumor area, and the imaging effect was the best. The results showed that after the injection of 12nmol A10-3.2-ICG, the tumor site under the fluorescence laparoscope could immediately (0min) produce significant fluorescence signals, and maintain the imaging effect for a sufficient period of time, indicating that A10-3.2-ICG was always highly concentrated in the tumor area. (b) shows the fluorescence distribution of the main organs and tumors in vitro 2h after injection. The tumor and kidney are the main concentrated areas of fluorescence signals, and other organs have no significant fluorescence signals, indicating that A10-3.2-ICG has a good targeted imaging effect on PCa and can clearly mark and display tumors.
[0063] Experimental Example 2: In vitro photothermal / photodynamic therapy of PCa with A10-3.2-ICG
[0064] PCa cell lines C4-2, 22Rv1 and PC3 were cultured under standard culture conditions and then divided into the following treatment groups: control group (PBS), laser irradiation group (Laser), A10-3.2 combined with laser irradiation group (A10-3.2+L), ICG combined with laser irradiation group (ICG+L) and A10-3.2-ICG combined with laser irradiation group (A10-3.2-ICG+L). Cells in each group were exposed to 808 nm, 1 W / cm 2After 5 minutes of laser irradiation, ROS detection and cell survival / death detection were performed. ROS detection: After the treatment of each group, the generation of intracellular ROS was detected by adding the fluorescent probe H2DCFDA. Subsequently, the fluorescence intensity of each group of cells was observed and recorded using a fluorescence microscope, and the ROS generation levels between different treatment groups were compared. Cell survival / death detection: After the treatment of each group, the cells were stained using the live / dead cell staining method, using Calcein-AM (marking live cells in green) and propidium iodide (PI, marking dead cells in red), and the cell staining results of different treatment groups were observed and photographed under a fluorescence microscope, and the survival and death of cells in each group were recorded.
[0065] The ROS generation effect of each group is as follows Figure 7 As shown, (a) fluorescence microscopy images show that in the PBS group, Laser group and A10-3.2+L group, the fluorescence signals of C4-2, 22Rv1 and PC3 cell lines were weak, and there was almost no obvious ROS generation; in the ICG+L group, the fluorescence signal intensity of the three cell lines was significantly enhanced, especially in the PC3 cell line; in the A10-3.2-ICG+L group, each cell line showed the strongest fluorescence signal, indicating that ROS generation reached the highest level, especially in the C4-2 and 22Rv1 cell lines. (b) Fluorescence quantitative analysis showed that in the 22Rv1 cell line, ROS generation in the ICG+L group and the A10-3.2-ICG+L group was significantly higher than that in the PBS group ( ** p<0.01, **** p<0.0001). The fluorescence intensity of the A10-3.2-ICG+L group was the highest, indicating that the ROS generated by the A10-3.2-ICG+L group with internalized A10-3.2-ICG was significantly higher than that of the ICG+L group that only relied on the free diffusion of ICG ( ### p<0.001). This enhanced effect indicates that A10-3.2-ICG effectively enhances the efficacy of photothermal therapy in 22Rv1 cells through PSMA-specific binding and internalization. In the C4-2 cell line, ROS generation in the ICG+L group and the A10-3.2-ICG+L group was also significantly higher than that in the PBS group ( ** p<0.01, **** p<0.0001). The C4-2 cell line expressed a high level of PSMA, which enabled A10-3.2-ICG to bind and internalize into the cells more effectively, resulting in the highest fluorescence intensity in the A10-3.2-ICG+L group, which was significantly higher than that in the ICG+L group ( ## p<0.01). In PC3 cell line, the fluorescence intensity of ICG+L group was significantly higher than that of PBS group ( ***p<0.001), while the fluorescence intensity of the A10-3.2-ICG+L group was lower than that of the ICG+L group ( ## p<0.01). PC3 is a PSMA-negative cell line, so A10-3.2-ICG cannot effectively bind to PSMA, and there is no internalization. ICG can only enter the cell by free diffusion, which makes A10-3.2-ICG less effective in PC3 cell line than ICG alone. This shows that in PSMA-negative cells, A10-3.2-ICG not only cannot enhance the photothermal effect, but may even affect the free diffusion of ICG due to the presence of the conjugate.
[0066] The results of cell survival / death assays in each group are shown in Figure 8 As shown, (a) fluorescence microscopy images showed that in the PBS group, Laser group and A10-3.2+L group, 22Rv1, C4-2 and PC3 cell lines mainly showed green fluorescence, indicating that most cells survived; in the ICG+L group, the red fluorescence signal increased significantly, indicating that more cells died; in the A10-3.2-ICG+L group, the red fluorescence signal was more significant, indicating that the proportion of cell death increased further; (b) quantitative analysis of the proportion of cell survival and death showed that compared with the PBS group, the proportion of cell death in the ICG+L group and the A10-3.2-ICG+L group was significantly increased ( **** p<0.0001), and the cell death rate in the A10-3.2-ICG+L group was significantly higher than that in the ICG+L group ( ### p<0.001), indicating that A10-3.2-ICG enhanced the photothermal therapeutic effect of ICG through the specific binding and internalization of PSMA. In the C4-2 cell line, the cell death rate in the ICG+L group and A10-3.2-ICG+L group increased significantly compared with the PBS group ( **** p<0.0001), and the cell death rate in the A10-3.2-ICG+L group was significantly higher than that in the ICG+L group ( #### p<0.0001), which may be attributed to the fact that A10-3.2-ICG enhanced the photothermal effect of ICG in these cells through binding and internalization. In the PC3 cell line, the proportion of cell death in the ICG+L group was significantly increased compared with the PBS group ( **** p<0.0001), which was mainly due to the free diffusion of ICG into cells and the photothermal effect; and compared with the ICG+L group, the cell death rate in the A10-3.2-ICG+L group was significantly reduced ( #### p<0.0001), which may be due to the lack of effective PSMA expression in PC3 cells, which prevents A10-3.2-ICG from effectively binding and internalizing, thus affecting the photothermal therapy effect.
[0067] Overall, the above results indicate that in PSMA-positive cell lines (such as 22Rv1), A10-3.2-ICG specifically binds to cell surface PSMA and is internalized into the cell, significantly enhancing the photothermal / photodynamic therapy effect, while in PSMA-negative cell lines (such as PC3), this specific binding and internalization does not exist or is extremely limited.
[0068] Experimental Example 3: In vivo targeted mPTT of PCa by A10-3.2-ICG
[0069] mPTT treatment flow chart Fig. 9 As shown, 15 3-4 week old athymic male BALB / c nude mice were purchased and raised normally. 100 μl of mixed solution was prepared with PBS and Matrigel at a volume ratio of 1:1, and 5×10 6 22Rv1 cells were implanted subcutaneously on the right chest wall of nude mice. Targeted mPTT was then performed on the 7th and 14th days after tumor formation. The treatment process was as follows: nude mice were anesthetized by intraperitoneal injection of pentobarbital (60 mg / kg), 6 nmol A10-3.2-ICG was injected into the tail vein, and 808 nm near-infrared light was used for 5 min at a fixed distance from the tumor surface. During the treatment, the temperature of the treatment area was monitored in real time to keep it roughly within the standard temperature range of mPTT (42-45°C).
[0070] Fig.10 The temperature changes of the subcutaneous tumor site of the experimental nude mice were shown from the start of treatment to 5 minutes. The thermal imaging image in the figure shows that the temperature of the target area was 39.2°C at the beginning. In the next 1 minute, the temperature rose rapidly to 42.3°C, and further increased to 45.1°C at 2 minutes. The temperature reached 46.6°C at 3 minutes, slightly dropped to 44.8°C at 4 minutes, but rose again to 46.6°C at 5 minutes. It can be seen that the use of A10-3.2-ICG for mPTT can significantly increase the temperature of the target site in a short time, indicating that A10-3.2-ICG has a good mPTT effect and can effectively concentrate heat in the PCa site during treatment, thereby enhancing the therapeutic effect.
[0071] Fig.11The experimental results of the inhibitory effect of mPTT on nude mouse tumor growth are shown. Figure (a) shows that at the end of the experiment, the tumor volume of the Control group was larger, while the tumor volume of the mPTT group was significantly reduced. This difference indicates that the tumor growth of nude mice in the mPTT group was significantly inhibited; Figure (b) shows the nude mouse tumors after removal. The tumor volume of the Control group was generally larger, while the tumor volume of the mPTT group was significantly reduced. The inhibitory effect of mPTT on tumor growth was further confirmed; Figure (c) shows the changes in nude mouse body weight. The body weights of the two groups of nude mice remained relatively stable throughout the experiment, and no significant differences were observed. This result shows that mPTT treatment did not have an adverse effect on the overall health of nude mice, and their body weight was not affected. Figure (d) shows the changes in tumor volume. The tumor volume of the Control group grew rapidly during the experiment, and the tumor volume of the mPTT group was significantly lower than that of the Control group after the 7th day ( * p<0.05), indicating that mPTT effectively inhibited tumor growth. By day 14, the tumor size was close to 1500 mm 3 , while the tumor volume in the mPTT group was significantly lower than that in the control group ( **** p<0.0001; Figure (e) Final tumor weight. The tumor weight of the Control group was significantly higher than that of the mPTT group ( **** p<0.0001), which were approximately 0.6 g and 0.2 g, respectively, further verifying the inhibitory effect of mPTT on tumor growth.
[0072] In summary, mPTT showed significant effects in inhibiting tumor growth. At the same time, mPTT treatment did not affect the body weight of nude mice, indicating that it has low toxicity and high safety. These data support mPTT as a potential tumor treatment and show its effectiveness in inhibiting tumor growth.
[0073] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.
Claims
1. An integrated probe for diagnosis and treatment of prostate cancer, It is characterized in that The probe is A10-3.2-ICG, which is composed of the PSMA-targeting RNA aptamer A10-3.2 coupled with ICG.
2. A diagnostic and therapeutic probe for prostate cancer according to claim 1, It is characterized in that The effective folding temperature is: heating at 95°C for 5 min, then heating to 26.6°C at a rate of 4.6°C / min and maintaining in the dark.
3. A diagnostic and therapeutic probe for prostate cancer according to claim 1, It is characterized in that The recommended dosage of the probe in immediate tumor fluorescence imaging and targeted photothermal therapy is no less than 6 nmol.
4. The diagnostic and therapeutic probe for prostate cancer according to claim 1, It is characterized in that A10-3.2 and ICG were covalently bound at a mass ratio of 1:
1.
5. Use of the integrated diagnostic and therapeutic probe for prostate cancer according to claim 1 in the preparation of an immediate real-time fluorescent imaging preparation for prostate cancer.
6. Use of the integrated diagnostic and therapeutic probe for prostate cancer according to claim 1 in the preparation of a prostate cancer targeted photothermal / photodynamic therapy preparation.
7. The use according to claim 5 or 6, It is characterized in that The prostate cancer is PSMA-positive prostate cancer.
